Basic HTML Version
34
ICCS 2012
POSTER ABSTRACTS
were connected to an earlier and higher incidence of CAV.
These results indicate the necessity for monitoring HLA and
non-HLA antibodies after HTx.
P7
IDENTIFICATION OF NON-HLA ANTIBODIES IN
VENTRICULAR ASSIST DEVICE RECIPIENTS
Markus J Barten, Sandy von Salisch, Maja T Dieterlen,
Stefan Dhein, Friedrich W Mohr, Hartmuth B Bittner Heart
Center Leipzig
Background:
Recipients of ventricular assist devices
(VADR) bridged to heart transplantation (HTx) have a higher
incidence to develop antibodies against human leukocyte
antigens (HLA). Beside HLA antibodies, non-HLA antibodies
like major histocompatibility complex class I-related chain
A (MICA) and autoantibodies against angiotensin type 1
receptor (AT1R) and endothelin receptor A (ETAR) are
implicated in the pathogenesis of acute rejection and
allograft vasculopathy. Therefore, we monitored non-HLA
and HLA antibodies in VADR during the first year after
implantation.
Methods:
For antibody screening, sera of 56
VADR were analyzed by Luminex-technology for HLA/MICA
and by ELISA for AT1R/ETAR antibodies several times over
one year after implantation.Blood transfusions, gender and
age were reviewed.
Results:
The average age of VADR was
53.6±13.4 years, including 26 men. Most of the VADR were
positive for AT1R (65.5%) and ETAR (68.9%) antibodies
(>17 U) with high antibody titres up to 1000 U (27.6% each)
or up to >2000 U (AT1R: 24.1%; ETAR: 34.5%). Almost half
of the VADR (48.2%) showed moderate titres of HLA and/
or MICA antibodies within the first year (anti-HLA-class
I: 27.5%, anti-HLA-class II: 24.1%, anti-MICA: 17.2%).
No significant difference in the number of received blood
products were observed between antibody-negative or
positive VADR, but AT1R/ETAR positive VADR received
a higher amount of blood transfusions (55.5±77.6 vs.
16.1±9.5).
Conclusions:
Beside HLA and MICA antibodies,
VADR show most notably high titres of autoreactive AT1R/
ETAR antibodies within the first year after VAD-implantation.
Our data underline the necessity for monitoring non-HLA
antibodies in VADR prior HTx.
P8
EVALUATION OF IMMUNE RECONSTITUTION IN
PATIENTS WITH FANCONI ANEMIA FOLLOWING
BONE MARROW ALLOGENIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION AND MYELOABLATIVE
CONDITIONING.
Miriam Perlingeiro Beltrame
1
, Dimas Tadeu Covas
2
, Rita
Perlingeiro
3
, Mariester Malvezzi
1
, Carmem Bonfim
1
, Ana
Paula Azambuja
1
, Maria Tadeu Rocha
1
, Noeli Silva
1
, Julie
Pimentel
1
, Yara Schluga
1
, Edna Martins
1
, Ricardo Pasquini
1
1
UFPR - Hospital de Clinicas,
2
Faculdade de Medicina de
Ribeirao Preto,
3
University of Minnesota
Fanconi anemia is an autosomal recessive or X-linked
disorder characterized by bone marrow aplasia. Allogeneic
haematopoietic cell transplantation (HCT) remains the only
treatment that can correct the haematological manifestations
in patients with Fanconi anaemia. We studied immune
recovery in 23 patients during one year pos HCT. The
mean age of patients was 9,6 years old and 7.6 in the
control group. By flow cytometry we evaluated T, B and
NK lymphocytes in blood and cytokines (IL-2, IL-4, IL-6,
IL-10, TNF and INF) in serum samples. The follow-up was
on days D+30, D+60, D+100, D+180, D+270, D+360 to
correlate these findings with immune response and compare
with pre transplant samples and the control group. The
following markers were performed;CD3,CD4,CD8, CD10,
CD16, CD19, CD20, CD24, CD25, CD27, CD28, CD31,
CD38, CD45, CD45RA,CD45RO,CD56, CD57, CD69,